Contribute Try STAT+ Today

Tweaking an immune protein called interleukin-18 can overcome tumors that lure it into binding with a decoy receptor protein and render it harmless to cancer cells, new research in mice shows. In conjunction with the paper, published Wednesday in Nature, a company founded by senior author Aaron Ring announced $25 million in initial financing to create and commercialize a drug based on the discovery.

The approach adds another weapon to an immunotherapy arsenal that activates immune responses hijacked by cancer. Checkpoint inhibitors, for example, take the brakes off immune cells that should battle invaders. IL-18 is a cytokine that normally activates T cells and natural killer cells, two immune forces that fight infection, but it’s disarmed by the decoy wielded by tumors. 

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • This article touches on an interesting question. How does a scientist with a discovery move the idea forward with an optimal balance between academia and investors?

Comments are closed.

Your daily dose of news in health and medicine

Privacy Policy